Filing Details
- Accession Number:
- 0001559647-17-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-04-07 12:50:33
- Reporting Period:
- 2017-04-06
- Filing Date:
- 2017-04-07
- Accepted Time:
- 2017-04-07 12:50:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
737207 | Marina Biotech Inc. | MRNA | Pharmaceutical Preparations (2834) | 112658569 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559647 | W. Joseph Ramelli | C/O Marina Biotech, Inc. 17870 Castleton Street, Suite 250 City Of Industry CA 91748 | Chief Executive Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-04-07 | 22,500 | $0.43 | 440,653 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2017-04-06 | 13,000 | $0.34 | 418,153 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.38 to $0.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
- The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.335 to $0.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.